Kidney diseases articles within Nature Reviews Endocrinology

Featured

  • News & Views |

    In the Steno-2 trial, 160 individuals with type 2 diabetes mellitus, mostly in their 50s, were randomly assigned to multifactorial interventions or conventional care. Whereas microvascular and macrovascular complications were reduced during the 7.8 years of the trial period with intensive therapy, the observational follow-up data at 13.3 years and, now, 21 years demonstrate a benefit on mortality.

    • Harpreet Bajaj
    •  & Bernard Zinman

  • News & Views |

    Lysosomal acid lipase deficiency can lead to liver failure and early death. A recently published placebo-controlled trial shows that enzyme-replacement therapy improves plasma levels of lipids and aminotransferases, and reduces liver fat content. However, the effect on clinical end points and an appropriate indication for treatment remain to be established.

    • Carla E. M. Hollak
    •  & G. Kees Hovingh

  • News & Views |

    In an analysis of data from NHANES spanning from 1999 to 2010, Tuot et al. address two linked questions. Which patients with diabetes mellitus and renal insufficiency are reasonable candidates for metformin therapy and how does this treatment depend on the approach used to measure renal function?

    • Zachary Bloomgarden

  • News & Views |

    In a new study published in The Lancet Diabetes & Endocrinology, metformin use is associated with significantly increased all-cause mortality in patients with type 2 diabetes mellitus and stage 5 chronic kidney disease (CKD). The findings support current recommendations that metformin should not be used in patients with stage 5 CKD.

    • Guntram Schernthaner
    •  & Marie Helene Schernthaner-Reiter

  • News & Views |

    In a prospective study of patients with type 1 diabetes mellitus, leisure time physical activity of low intensity at baseline (versus high intensity) was associated with the development and progression of nephropathy. This finding is consistent with previous reports that exercise delays the progression of chronic kidney disease in people with or without diabetes mellitus.

    • George Jerums
    •  & Richard J. MacIsaac

  • News & Views |

    A recent cohort study has shown that cardiac autonomic neuropathy (CAN) is associated with increased albuminuria and decreased estimated glomerular filtration rate (eGFR) at baseline and is predictive of a subsequent decline in eGFR. Could CAN be used to identify patients who are at increased risk of early decline in eGFR?

    • George Jerums
    •  & Richard J. MacIsaac

  • News & Views |

    Low circulating levels of vitamin D metabolites were found to be associated with development of microalbuminuria in patients with type 1 diabetes mellitus from the DCCT/EDIC study. Could interventions aimed at improving vitamin D levels be a new option for the prevention of diabetic kidney disease?

    • Peter Rossing
    •  & Christel Joergensen

  • News & Views |

    Glomerular hyperfiltration has long been thought of as indicative of progression to albuminuria and nephropathy in type 1 diabetes mellitus. However, a new study supports other research in the past few years that has highlighted flaws in this model for kidney disease pathogenesis in type 1 diabetes mellitus.

    • Christos Chatzikyrkou
    •  & Hermann Haller

  • News & Views |

    Treatment options for osteoporosis are limited for older individuals with chronic kidney disease. A secondary analysis of the FREEDOM trial sheds light on the efficacy and safety of denosumab in patients with impaired kidney function, but underlines that challenges remain in the treatment of osteoporosis in patients with severe chronic kidney disease.

    • Jorge B. Cannata-Andía
    •  & Carlos Gómez-Alonso

  • News & Views |

    Despite the many advances in understanding and treating diabetes mellitus and diabetes-related kidney disease, progression of nephropathy, which ultimately leads to end-stage kidney disease, remains unstoppable. In the FIELD study, Davis et al. assert that long-term fenofibrate treatment in patients with type 2 diabetes mellitus might resolve this problem.

    • Suneel M. Udani
    •  & George L. Bakris

  • Review Article |

    This Review summarizes the role of reactive oxygen species and oxidative stress in diabetes mellitus and in the pathogenesis of endothelial cell dysfunction and diabetic nephropathy. Furthermore, the authors explore possible therapeutic interventions to reduce oxidative stress and endothelial cell dysfunction and retard the progression of diabetic nephropathy.

    • Dhruv K. Singh
    • , Peter Winocour
    •  & Ken Farrington

  • News & Views |

    Combination therapy with vitamins B6, B9 and B12 is a therapeutic intervention to decrease levels of plasma homocysteine and the risk of cardiovascular disease. However, a recent trial found that cosupplementation with these vitamins exacerbated the decline in renal function and increased the risk of vascular disease in patients with diabetic nephropathy. Confidence in this high-dose vitamin supplement is shaken.

    • Paul J. Thornalley
    •  & Naila Rabbani

Browse broader subjects

Browse narrower subjects

Browse Kidney diseases across other nature.com journals